• Emma Ross, Aideen Maguire, Adrian Mairs, Clare Hall, Michael J C Donnelly, and Dermot P J O'Reilly.
• Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom. Electronic address: e.ross@qub.ac.uk.
• Am J Prev Med. 2021 Mar 1; 60 (3): e123-e130.

IntroductionAlthough there is evidence of disparities in breast cancer screening for women with mental illness in the U.S., there is a dearth of studies examining this association in the United Kingdom, where health care is provided free at the point of access. This population-based study examines the influence of mental illness, as assessed by the uptake of psychotropic medications, on breast screening uptake in the United Kingdom.MethodsA cohort of 57,328 women identified from 2011 Census records within the Northern Ireland Longitudinal Study was followed through a single 3-year screening cycle (2011-2014) of the National Health Service Breast Screening Programme. Mental illness was identified by a receipt of psychotropic medication in the 3 months preceding screening invite. Individual- and household-level attributes were derived from Census records. Data were analyzed in 2019.ResultsMore than a third of women received ≥1 prescription for psychotropic medication in the 3 months preceding screening invite. The odds of attendance in these individuals were reduced by 15% (OR=0.85, 95% CI=0.81, 0.88). Attendance was particularly low for women prescribed antipsychotics (OR=0.63, 95% CI=0.56, 0.70), anxiolytics (OR=0.61, 95% CI=0.57, 0.66), and hypnotics (OR=0.68, 95% CI=0.63, 0.72).ConclusionsThese findings confirm the existence of significant disparities in breast screening uptake for women with mental illness. Targeted interventions are warranted to prevent avoidable breast cancer deaths in these individuals, especially given the increasing prevalence of mental illness.Copyright © 2020 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

12 keywords...

hide…